riluzole has been researched along with Kidney Neoplasms in 1 studies
Riluzole: A glutamate antagonist (RECEPTORS, GLUTAMATE) used as an anticonvulsant (ANTICONVULSANTS) and to prolong the survival of patients with AMYOTROPHIC LATERAL SCLEROSIS.
Kidney Neoplasms: Tumors or cancers of the KIDNEY.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Treatment with riluzole, a glutamate release inhibitor, has been previously shown to be safe in melanoma patients and produced biologic effects, but did not lead to radiographic responses, possibly due to poor pharmacokinetic properties." | 5.51 | A phase Ib dose-escalation study of troriluzole (BHV-4157), an oral glutamatergic signaling modulator, in combination with nivolumab in patients with advanced solid tumors. ( Berman, RM; Chan, N; Chen, S; Coric, V; Girda, E; Groisberg, R; Malhotra, J; Mehnert, JM; Palmeri, M; Saraiya, B; Saunders, T; Shih, W; Silk, AW; Spencer, K; Vieth, J; Zloza, A, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Silk, AW | 1 |
| Saraiya, B | 1 |
| Groisberg, R | 1 |
| Chan, N | 1 |
| Spencer, K | 1 |
| Girda, E | 1 |
| Shih, W | 1 |
| Palmeri, M | 1 |
| Saunders, T | 1 |
| Berman, RM | 1 |
| Coric, V | 1 |
| Chen, S | 1 |
| Zloza, A | 1 |
| Vieth, J | 1 |
| Mehnert, JM | 1 |
| Malhotra, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I Study to Evaluate the Safety of Trigriluzole (FC-4157/BHV-4157) in Combination With PD-1 Blocking Antibodies[NCT03229278] | Phase 1 | 14 participants (Actual) | Interventional | 2017-10-03 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The MTD of trigriluzole in combination with nivolumab will be identified. The MTD will then be tested in combination with pembrolizumab using the same escalate/de-escalate/stay rules. Data on the adverse event type, severity and frequency will be recorded. (NCT03229278)
Timeframe: Four weeks
| Intervention | mg (Number) |
|---|---|
| All Participants | 420 |
A DLT was any Grade 3 or 4 adverse event (AE) using the Common Terminology Criteria for Adverse Events Version 3.0 (CTCAE 3.0) that was possibly Trigriluzole or Nivolumab related. CTCAE 3.0 Grade 3 is a severe AE and Grade 4 is a life- threatening or disabling AE. DLTs were collected to determine the Maximum-Tolerated Dose (MTD), which is defined as the dose level below the dose at which 33% of participants experienced a DLT. (NCT03229278)
Timeframe: Four weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Experimental: Nivolumab 240mg IV Every 2 Weeks - Trigriluzole 140 mg Taken by Mouth Daily (PO) | 0 |
| Experimental: Nivolumab 240mg IV Every 2 Weeks - Trigriluzole 140 mg PO Twice a Day (BID) | 0 |
| Experimental: Nivolumab 240mg IV Every 2 Weeks - Trigriluzole 140 mg /280mg | 1 |
| Experimental: Nivolumab 240mg IV Every 2 Weeks - Trigriluzole 280mg PO BID | 2 |
Continuous variables will be presented by summary statistics (such as mean, median, standard error and 95% confidence intervals [CI]) and the categorical variables by frequency distributions (i.e., frequency counts, percentages and 95% CI). (NCT03229278)
Timeframe: Up to 3 years
| Intervention | percentage of participants (Number) |
|---|---|
| Nivolumab 240mg IV Every 2 Weeks - Trigriluzole 280mg PO BID | 7 |
1 trial available for riluzole and Kidney Neoplasms
| Article | Year |
|---|---|
A phase Ib dose-escalation study of troriluzole (BHV-4157), an oral glutamatergic signaling modulator, in combination with nivolumab in patients with advanced solid tumors.
Topics: Bayes Theorem; Carcinoma, Renal Cell; Enzyme Inhibitors; Glutamates; Humans; Kidney Neoplasms; Melan | 2022 |